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PROTECTIVE EFFECT OF 
NICORANDIL AS AN 
ADDITIVE TO THE SOLUTION 
FOR CONTINUOUS WARM 
CARDIOPLEGIA 
Experiments were designed to assess whether (1) nicorandil given before global 
low-flow ischemia or (2) included in low-flow continuous cardioplegia im- 
proved the recovery of cardiac function in the isolated rat heart. The first 
investigated the effect of nicorandil (2, 10, or 100 pmoUL), given for 3 minutes 
before 30 minutes of normothermic global ischemia, on recovery after 30 
minutes of reperfusion. In aerobically perfused hearts, doses of 10 and 100 
txmol/L significantly increased coronary flow; the dose of 100/xmol/L exerted 
a negative inotropic effect. These doses hortened the time to contractile arrest 
(282 -+ 18 and 276 +- 22 seconds versus 354 -+ 16 seconds in the control hearts 
with unmodified ischemia; p < 0.05 in both instances). Nicorandil also 
improved the postischemic recovery of coronary flow (79.1% _ 1.7% and 78.0% 
_+ 1.6%, respectively, versus 71% - 1.8%; p < 0.05). However, there was no 
significant improvement in recovery of contractile function, creatine kinase 
leakage, or tissue adenosine triphosphate and creatine phosphate contents. 
Second, pretreatment with nicorandil (10 /LmoUL) was shown to increase 
susceptibility ofthe hearts to reperfusion-induced v ntricular fibrillation from 
0% (n = 8) in control hearts to 50% in the drug-treated group (p < 0.05). 
Third, nicorandii (10/xmoUL) was added to cardioplegic and noncardioplegic 
solutions infused into the coronary tree throughout 100 minutes of low-flow 
(0.7 ml/min) ischemia: in eight of nine control hearts electrical activity was 
maintained throughout, whereas in all nicorandil-treated hearts electrical 
activity was suppressed for at least part of the time. Nicorandil also reduced 
the prevalence of ischemic ontracture to 0% during continuous infusion of 
cardioplegic solution (compared with 30% in nicorandil-free control hearts) 
and improved the recovery of contractile function after 40 minutes of reperfu- 
sion. Thus, in the noncardioplegia groups, left ventricular developed pressure 
recovered to 77.8% - 4.0% versus 51.7% -+ 2.6% in control hearts (p < 0.05) 
and in the cardioplegia groups to 96.2% - 4.2% versus 79.7% -+ 5.5% (p < 
0.05). Ventricular compliance (the ventricular volume required to achieve a left 
ventricular end-diastolic pressure of 4 mm Hg) was better preserved in the 
nicorandil-containing noncardioplegia group (133 --- 6/LI) than in the control 
group (88 - 10 pl; p < 0.05). In conclusion, nicorandil has been shown to (1) 
reduce ischemic ontracture, (2) lessen the effects of ischemic arrest, and (3) 
improve the postischemic recovery of contractile function. In this species and 
preparation it may, however, enhance vulnerability to reperfusion-induced 
arrhythmias. (J THORAC CARDIOVASC SURG 1995;110:1063-72) 
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N icorandil, a nicotinamide nitrate with the ability 
to promote opening of the adenosine triphos- 
phate (ATP)-sensitive potassium channel, has been 
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shown to protect against injury during ischemia nd 
reperfusion in a variety of experimental models and 
species. 1-3 It may either reduce infarct size after 
severe regional ischemia or attenuate stunning after 
a brief period of global ischemia. The underlying 
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protective mechanism is thought o be a direct effect 
operative through the activation of ATP-sensitive 
potassium channels. 3 It has also been suggested, 
however, that part of the protective effect might 
involve the acceleration of  the onset of ischemic 
arrest, that is, a cardioplegic effect, which thereby 
conserves the limited supplies of ATP  during isch- 
emia. 2 In addition, nicorandil might provide added 
protection by nitrate-mediated (and potassium 
channel-mediated) effects on coronary flow. 4 This 
property distinguishes it f rom other drugs in its 
class. 
Continuous warm delivery of cardioplegic solu- 
tion, which minimizes ischemia and avoids hypo- 
thermia, has recently been advocated as a new 
approach to myocardial preservation during coro- 
nary bypass operations. 5'6 However, cardiac electri- 
cal activity may resume during this procedure, 6'7 
and this may limit the protective ffect. Maintenance 
of electrical quiescence of the heart is important not 
only to maximize recovery of cardiac function, but 
also to facilitate surgical correction. 
It may be hypothesized that the addition of  a 
potassium-channel opener to the solution used for 
continuous warm cardioplegia may help to ensure 
cardiac electrical arrest and improve the recovery of 
cardiac function. We have therefore studied the 
effect of nicorandil as an additive in the use of  this 
form of cardioplegia nd have assessed whether it is 
of  any benefit in the absence of cardioplegia, either 
as pretreatment or continuously administered 
throughout a period of reduced coronary flow. 
Material and methods 
Animals and drugs. Adult male rats (220 to 280 gm 
body weight) of the Wistar strain were used in the study. 
The animals received humane care in compliance with the 
"Principles of Laboratory Animal Care" formulated by 
the National Society for Medical Research and the 
"Guide for the Care and Use of Laboratory Animals" 
prepared by the National Academy of Sciences and pub- 
lished by the National Institutes of Health (NIH Publica- 
tion No. 80-23, revised 1985). Nicorandil was donated by 
Rh6ne-Poulenc Rorer, Antony, France. 
Perfusion preparation. Rats were anesthetized with 
diethyl ether and heparinized (1000 IU/kg, intravenously); 
30 seconds later the heart was excised and placed in cold 
(4 ° C) perfusion solution until contraction had ceased. 
The aorta was mounted on a stainless teel cannula, the 
pulmonary artery incised to facilitate coronary drainage, 
and the heart subjected to nonrecirculating Langendorff 
perfusion (37 ° C) at a pressure quivalent to 100 cm H20. 
The perfusion solution was bicarbonate buffer, containing 
(in rnillimoles per liter) glucose 11.1, NaC1 118.5, KC1 
4.75, MgSO 4 1.19, KHzPO 4 1.18, NaHCO 3 25.0, and 
CaC12 1.36. This solution was gassed with 95% 0 2 plus 5% 
CO2 (pH 7.4 at 37 ° C) and filtered before use through a 
5 ~m porosity membrane to remove any particulate 
matter. A side arm of the aortic cannula allowed either 
infusion with cardioplegic solution or the establishment of
continuous low-flow perfusion by a pump set at a constant 
flow rate. 
Cardioplegic solution. The cardioplegic solution was 
prepared by mixing the Fremes' solution 7 (containing, in 
millimoles per liter, KC1 30, MgSO 4 9, tromethamine 
(THAM) 12, and glucose 250 plus citrate-phosphate- 
dextrose solution 20 ml/L) with perfusion solution in a 
ratio of 1:4. The final solution contained (in millimoles 
per liter) NaC1 95.0, KC1 9.8, MgC12 2.8, CaC12 1.1, 
NaHCO 3 20.0; THAM 2.4, and glucose 58.9, at pH 7.4. 
During the initial 3 minutes of infusion with this solution, 
the potassium concentration was increased to 26 mmol/L 
to achieve a rapid cardiac arrest. 6' 7 The cardioplegic 
solution was filtered before use through a 5 ~m porosity 
membrane and gassed with 95% 02 plus 5% CO 2. The 
solution was kept in a temperature-regulated r servoir 
(37 ° C) and infused through a side arm of the aortic 
cannula at a constant flow rate of 0.7 ml/min. 
Experimental protocols 
Study L" Dose-response tudy of nicorandil as preischemic 
treatment. This protocol was designed to assess the ability 
of nicorandil to shorten the time to arrest during ischemia 
and also its ability, when given as pretreatment, to im- 
prove the postischemic recovery of cardiac function. 
Three doses of nicorandil (2, 10, and 100 ~mol/L) were 
studied. Four groups of hearts (6 per group) were initially 
perfused aerobically for 10 minutes; a fluid-containing 
compliant balloon, attached to the proximal end of a 
cannula, was then introduced into the left ventricle 
through the mitral valve. The distal end of the cannula was 
connected to a pressure transducer to permit recording of 
the intraventricular p essure. The balloon was next filled 
with sufficient fluid to produce an end-diastolic pressure 
of 4 mm Hg. Control measurements of cardiac function, 
including left ventricular developed pressure (LVDP), left 
ventricular end-diastolic pressure (LVEDP), and coro- 
nary flow, were recorded 10 minutes later. The hearts 
were then subjected to 3 minutes of continuous perfusion 
with oxygenated perfusion buffer, to which had been 
added varying doses of nicorandil (0, 2, 10, or 100 
/~mol/L). This was followed by 30 minutes of normother- 
mic global ischemia and 30 minutes of reperfusion. All 
hearts were paced at 320 beats/min during the preischemic 
and reperfusion periods. Cardiac contraction was re- 
corded on chart paper and time to mechanical arrest for 
each heart after the onset of ischemia was analyzed 
retrospectively. Intraventricular pressure was monitored 
continuously during ischemia to assess ischemic ontrac- 
ture. During reperfusion, LVDP, LVEDP, and coronary 
flow were monitored and coronary effluent was collected 
and taken for the determination of total creatine kinase 
(CK) leakage, which was expressed in international units 
per 30 min/gm dry weight. If sustained ventricular fibril- 
lation (VF) occurred during reperfusion, the heart was 
gently compressed. All fibrillating hearts were successfully 
defibrillated by this method. 
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Study II: The effect of nicorandil pretreatment onvulner- 
ability to reperfusion-induced arrhythmias. On the basis of 
the preceding study, a 10/xmol/L dose of nicorandil was 
selected for assessment of the effect of pretreatrnent on 
the susceptibility of the heart to reperfusion-induced 
arrhythmias after global ischemia. Two groups of hearts 
were studied by a protocol similar to that described in the 
previous ection (except hat the hearts were not paced). 
Hearts (8 per group) were initially perfused aerobically 
for 20 minutes and this was followed by a 3-minute period 
of perfusion with oxygenated buffer with or without added 
nicorandil (10 tzmol/L). The hearts were then subjected to 
20 minutes of normothermic global ischemia and 10 
minutes of aerobic reperfusion. A unipolar electrogram 
was obtained via silver electrodes attached to the left 
ventricular free wall. This was displayed on a digital 
storage oscilloscope and recorded on chart paper through- 
out the experiment to permit the retrospective analysis of 
changes in the heart rate and of the occurrence of 
arrhythmias. In view of their arrhythmogenic effects, 
intraventricular balloons were not used in this series of 
studies. Heart rate, time to arrest of ventricular electrical 
activity, and the prevalence of reperfusion-induced ven- 
tricular fibrillation and tachycardia were derived from the 
electrogram traces. 
Study III: The effect of nicorandil during low-flow isch- 
emia with or without cardioplegia. On the basis of the 
results of the previous dose-response tudy, nicorandil in 
a dose of 10/xmol was also used in study III. Four groups 
of hearts (9 per group) were aerobically perfused for 20 
minutes and control values for LVDP, LVEDP, and 
cardiac flow were recorded. The hearts were then sub- 
jected to low-flow perfusion (0.7 ml/min) with either 
oxygenated buffer with or without added (10 /zmol/L) 
nicorandil (groups 1 and 2) or cardioplegic solution with 
or without added (10 txmol/L) nicorandil (groups 3 and 4). 
The low-flow rate (0.7 ml/min for a heart of 1 gm wet 
weight) was selected so as to match the myocardial oxygen 
consumption of the arrested heart (approximately 10% of 
the oxygen consumption that occurs during normal con- 
tractile activity) and to mimic the flow used in the clinical 
setting during continuous delivery of warm cardioplegic 
solution (>200 to 300 ml/min for a heart of 500 gm wet 
weight). During the period of low-flow perfusion the 
aortic pressure was greater than 20 mm Hg and the 
infused solution was mainly recovered in the coronary 
effluent, which suggests that the aortic valve remained 
competent during this time. Finally, all hearts were aero- 
bically reperfused for 40 minutes at a perfusion pressure 
equivalent to 100 cm HzO. Hearts were paced at a rate of 
320 beats/min before and after the period of low-flow 
perfusion. 
For the assessment of control contractile function, the 
intraventricular balloon was inflated with sufficient water 
to generate an LVEDP of 4 mm Hg; the LVDP and 
volume of the balloon were recorded. During low-flow 
perfusion, cardiac electrical activity was continuously 
monitored by means of an electrode attached to the left 
ventricle. To avoid overstretching of the left ventricle 
during low-flow perfusion, the volume of the balloon was 
reduced to one third of its control value. At the end of the 
reperfusion period, the balloon was reinflated to achieve 
an LVEDP of 4 mm Hg, and the LVDP and balloon 
volume were again recorded. 
Coronary effluent was collected throughout the reper- 
fusion period and this was taken for the determination of
CK leakage. At the end of the experiment, six hearts in 
each group were freeze-clamped and taken for assessment 
of tissue ATP and creatine phosphate contents. 
Exclusion criteria. During preischemic perfusion, any 
heart with a coronary flow rate less than 7 ml/min or an 
LVDP less than 90 mm Hg (at an LVEDP of 4 mm Hg) 
was excluded. Fewer than 10% of all hearts were ex- 
cluded. 
Statistical analysis. All results are expressed as the 
mean plus or minus the standard error of the mean and an 
analysis of variance was used for multiple comparisons. 
When a significant F value was obtained, comparison 
between means was done by Tukey's test. A two-tailed 
unpaired t test was used for comparison between two 
means when appropriate. A difference was considered 
statistically significant if p < 0.05. 
Results 
Study I: Dose-response study of nicorandil as 
preischemic treatment 
Preischemic cardiac function. Before the adminis- 
tration of  nicorandil, there were no differences in 
coronary flow or LVDP among the study groups 
(Fig. 1). After 3 minutes of perfusion with nicoran- 
dil-containing buffer, there was a dose-dependent 
increase in coronary flow, which, at the highest 
concentration (100 t~mol/L) reached 34% _+ 5% 
higher than the control value (from 12.1 _+ 0.3 to 
16.2 _+ 0.4 ml/min;p < 0.05) (Fig. 1). There were no 
statistically significant changes in LVDP in the 
hearts that received nicorandil at concentrations of  
2 and 10/xmol/L; however, a small (9% +_ 3%) but 
significant (p < 0.05) decrease in LVDP was ob- 
served in the hearts perfused with nicorandil at a 
concentration of 100/zmol/L (Fig. 1). 
The time to cardiac arrest after induction of isch- 
emia. Pretreatment with nicorandil at dosages of 10 
and 100/~mol/L accelerated the time to contractile 
arrest induced by ischemia (Table I). Pretreatment 
with nicorandil at a dose of 2 p, mol/L had no 
significant effect (Table I). 
lschemic ontracture. Ischemic contracture devel- 
oped in hearts in all study groups. The time to onse.t 
of contracture and the level of  peak contracture 
were similar in all groups (Table I). 
Post&chemic recovery of cardiac function. Fig. 2 
shows the profile for the recovery of coronary flow 
in the four study groups. At  the end of 30 minutes of  
reperfusion, a significantly better recovery of  coro- 
nary flow was observed in the hearts that received 
preischemic nicorandil at concentrations of 10 and 
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Fig. 1. Effect of nicorandil pretreatment on (A) preisch- 
emic coronary flow (CF) and (B) preischemic LVDP. 
Hearts (6 per group) were aerobically perfused for 20 
minutes and then subjected to 3 minutes of infusion with 
nicorandil at concentrations of 2, 10, and 100 txmol/L. 
Values are presented as means plus or minus standard 
error of mean. *p < 0.05 when compared with value 
before administration of nicorandil. 
100 txmol/L (9.4 _ 0.2 and 9.4 ___ 0.2 ml/min versus 8.6 
--- 0.2 ml/min in control hearts; p < 0.05 in both 
instances). The recovery of coronary flow in the hearts 
receiving a 2 t~mol/L dose of nicorandil tended to be 
lower than that in control hearts during the initial 
reperfusion period, but the difference failed to achieve 
statistical significance and by the end of the reperfu- 
sion period the recoveries were similar (8.8 ___ 0.2 
versus 8.6 _+ 0.2 ml/min; p = not significant). 
There were no statistically significant differences 
in LVDP and LVEDP among the four study groups 
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Fig. 2. Effect of nicorandil pretreatment (6 hearts per 
group) on postischemic recovery of coronary flow (CF). 
Values are presented as means plus or minus standard 
error of mean. *p < 0.05 when compared with untreated 
control group. 
Table I. Effect of nicorandil on time to cardiac 
arrest and severity of ischemic ontracture (6 hearts 
per group) 
Nicorandil Time to Time to onset Peak 
Study pretreatment arrest of contracture contracture 
group (pmol/L) (sec) (rain) (ram Hg) 
1 0 354 -+ 16 12.1 -4- 0.8 56.2 4- 3.2 
2 2 302 _+ 21 13.8 _+ 0.7 54.3 --- 3.6 
3 10 282 ± 18" 13.2 _+ 0.8 60.0 _+ 4.2 
4 100 276 ± 22* 14.0 _+ 0.6 61.8 ± 6.2 
Data expressed as means plus or minus standard error of mean. 
*p < 0.05 when compared with group 1 (control). 
Table II. Effect of nicorandil on postischemic 
contractile function and CK leakage (6 hearts per 
group) 
Nicorandil CK leakage 
Study pretreatment LVDP LVEDP (IU/30 min/gm 
group (lamol/L) (mm Hg) (mm Hg) dry wt) 
1 0 46.2 + 6.4 47.4 ± 3.8 148.8 + 17.1 
2 2 47.8 -+ 4.2 48.6 -- 4.2 153.9 -+ 18.2 
3 10 51.8 + 5.8 52.6 ± 5.8 148.2 +- 20.5 
4 100 43.4 -+ 4.6 50.6 ± 3.3 137.4 + 16.5 
Data expressed as means plus or minus standard error of mean. 
at the end of the reperfusion period, nor were there 
any differences in CK leakage during reperfusion 
(Table II). 
Study II: The effect of nicoranflil pretreatment on 
vulnerability to reperfusion-induced arrhythmias. 
Fig. 3 summarizes the time course for arrhythmias 
during the 10-minute period of reperfusion in indi- 
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Table III. Cardiac function before cardioplegia or 
low-flow perfusion (9 hearts per group) 
Study CF L VDP 
group Treatment (ml/min ) (ram Hg) 
1 Low-flow 11.8 ± 1.1 126 ±- 6 
2 Low-flow + nicorandil 11.6 -+ 0.8 128 ± 6 
3 Cardioplegia 12.0 ± 0.6 120 ± 4 
4 Cardioplegia + nicorandil 12.4 ± 0.6 117 ± 8 
Data expressed as means plus or minus standard error of mean. CF, 
Coronary flow. 
vidual hearts in the nicorandil-treated (10 /~mol/L 
for 3 minutes) and nicorandil-free groups. Nicoran- 
dil significantly (p < 0.05) increased the prevalence 
of reperfusion-induced VF and delayed the restora- 
tion of sinus rhythm. Thus four of the eight hearts 
had VF in the nicorandil-treated group (defibrilla- 
tion was not used in this study) whereas no heart in 
the control group had VF. 
Study III: The effect of nicorandil during low-flow 
ischemia with or without cardioplegia 
Electrical activity during low-flow perfusion and 
continuous infusion of cardioplegic solution. Before 
the induction of cardioplegia with continuous car- 
dioplegia or low-flow perfusion, there were no dif- 
ferences in coronary flow or LVDP among the four 
study groups (Table III). Fig. 4 shows the occur- 
rence of electrical activity during low-flow perfusion 
and continuous cardioplegia with or without added 
(10 txmol/L) nicorandil. In the hearts subjected to 
low-flow perfusion without nicorandil, electrical ac- 
tivity was sustained in nearly all hearts (8/9) 
throughout the 100 minutes. Nicorandil attenuated 
the electrical activity in all hearts during the first 10 
to 30 minutes. However, the activity recurred in all 
hearts after 40 to 60 minutes irrespective of the 
presence or absence of nicorandil. During continu- 
ous infusion of cardioplegic solution most hearts 
were electrically quiescent for a large part of the 100 
minutes of low-flow perfusion. However, in the 
nicorandil-free group electrical activity returned in 
three hearts after 40 to 60 minutes whereas in the 
nicorandil-treated group this only occurred in one 
heart. 
Ischemic ontracture. The perfusion pressure dur- 
ing continuous cardioplegia or low-flow perfusion 
was similar in all four groups (30 to 40 mm Hg). The 
prevalence of ischemic ontracture in the continu- 
ous cardioplegia without nicorandil group was 33% 
(3/9), whereas in the nicorandil group and the 
groups with low-flow perfusion with or without 
nicorandil, ischemic ontracture was absent. 
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Fig. 3. Effect of nicorandil on time to onset, preva- 
lence, and duration of reperfusion-induced arrhythmias 
in individual hearts (8 per group). All hearts were 
subjected to 20 minutes of normothermic global isch- 
emia and 10 minutes of reperfusion. Hearts in treated 
group were subjected to 3-minute infusion of nicorandil 
(10 ~mol/L) before onset of ischemia. VT, Ventricular 
tachycardia. 
Postischemic coronary flow. Fig. 5 shows the pro- 
file for the recovery of coronary flow in the four 
study groups. Recovery in the continuous cardiople- 
gia groups and in the low-flow perfusion with nic- 
orandil group was statistically significantly better 
than that in the low-flow perfusion alone group 
during the first 30 minutes of reperfusion. However, 
by the end of 40 minutes of reperfusion, there were 
no significant differences among the four study 
groups. 
Postischernic ontractile function. At the end of 
the 40-minute reperfusion period, the recovery of 
LVDP was improved in the nicorandil group in the 
continuous low-flow groups both with and without 
cardioplegia (Fig. 6, top). Hearts receiving continuous 
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Fig. 4. Effect of nicorandil on electrical activity during 
100 minutes of low-flow perfusion in individual hearts (9 
per group). Hearts were subjected either to low-flow 
buffer perfusion or to infusion of warm cardioplegic 
solution with or without nicorandil (10/,mol/L). 
infusion of cardioplegic solution with nicorandil recov- 
ered better than those receiving only continuous infu- 
sion of cardioplegic solution; hearts subjected to low- 
flow perfusion with nicorandil also recovered better 
than those subjected to low-flow perfusion without 
nicorandil. The ventricular compliance, as assessed by 
the volume of the balloon required to generate an 
LVEDP of 4 mm Hg was also better preserved in 
the nicorandil group (Fig. 6, bottom). However, 
when the LVDP of each group was assessed with 
equal volumes (120 /~1) of water in the intraven- 
tricular balloons, no significant difference in 
LVDP was seen (results not shown). There was no 
significant difference in the severity of reperfu- 
sion-induced arrhythmias among the four groups. 
CK leakage and tissue A TP and creatine phosphate 
contents. There were no statistically significant dif- 
ferences in mean leakage of CK or in ATP and 
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Fig. 5. Recovery of coronary flow after 100 minutes of 
low-flow perfusion or infusion of warm cardioplegic solu- 
tion with or without nicorandil (10 /~mol/L). Values are 
presented as means plus or minus standard error of mean. 
During first 30 minutes of reperfusion, coronary flow in 
nicorandil-treated group and cardioplegia groups recov- 
ered better (p < 0.05) compared with recovery in un- 
treated control group (9 hearts per group). 
creatine phosphate contents between the study 
groups at the end of experiment (Table IV). 
Discussion 
The present study in the isolated rat heart dem- 
onstrated that the inclusion of nicorandil in the 
solution used for continuous low-flow warm crystal- 
loid cardioplegia improved the recovery of contrac- 
tile function on restoration of full flow. Nicorandil 
also accelerated the onset of cardiac arrest and 
suppressed cardiac electrical activity during low-flow 
perfusion with or without cardioplegia. Despite this, 
the agent had no significant effect on CK leakage or 
tissue high-energy phosphate content. It is interest- 
ing to note that, although pretreatment with nic- 
orandil accelerated the onset of cardiac arrest and 
improved the postischemic recovery of coronary 
flow, it had no beneficial effect on the recovery of 
LVDP. Pretreatment with nicorandil, however, in- 
creased susceptibility to reperfusion-induced ar- 
rhythmias. 
Advantages and disadvantages of continuous low- 
flow cardioplegia. Continuous cardioplegia involves 
normothermic potassium arrest maintained by con- 
tinuous perfusion of a warm (37 ° C) cardioplegic 
solution. This procedure avoids the possible side 
effects of hypothermia nd minimizes the extent of 
high-energy phosphate depletion and calcium over- 
load. As a consequence, continuous cardioplegia has 
been used in patients at high risk undergoing valvu- 
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lar operations or revascularization procedures, s On 
the negative side, occasionally a heart cannot re- 
main arrested with warm cardioplegia nd may 
fibrillate or beat, thereby reducing the protective 
value of the procedure. The danger of overloading 
the patient with potassium and the possible detri- 
mental effects of high concentrations of potassium 
on the endothelium 9 preclude solving the problem 
by increasing the potassium concentration of the 
warm cardioplegic solution. When cardiac ontrac- 
tions resume, hypothermia and continuous infusion 
of cold cardioplegic solution may have to be 
used; 7however, this is contrary to the fundamen- 
tal principle of protection by warm cardioplegia 
and the protective ffect may again be reduced. 
The present study has demonstrated that the 
problem might be solved through the inclusion of 
a potassium-channel opener such as nicorandil in 
the solution used for continuous cardioplegia. 
Our results indicate that this can accelerate the 
onset of cardiac arrest, limit the resumption of 
electrical activity, and improve the recovery of 
contractile function. However, the present study 
does not allow us to determine whether the 
beneficial effect of nicorandil on the recovery of 
contractility was because of an antiischemic effect, 
a reduction in electrical activity, or both. 
The protective actions of nicorandil and potassi- 
um-channel openers during ischemia. Nicorandil 
exerts a variety of cardioprotective effects against 
injury in several experimental models of myocardial 
ischemia nd reperfusionJ -3 Evidence suggests that 
these effects may be a direct consequence of ATP- 
sensitive potassium-channel activation. 3'4 During 
the early moments of ischemia, potassium channels 
are thought o be activated as a consequence of 
various regulatory changes, including a decrease in 
tissue ATP levels and an increase in adenosine 
diphosphate l vels. ~°'al It has been hypothesized 
that potassium-channel activation can increase K + 
efflux or conductance and, as a consequence, pro- 
duce a hyperpolarization from the resting mem- 
brane potential toward the equilibrium potential for 
K+.Zo, la This hyperpolarization is thought o close 
voltage-dependent Ca 2+ channels (or prevent he 
opening of these channels on exposure to depolar- 
izing stimuli) and, as a result, to inhibit cardiac 
contraction.2. 12 This inhibitory effect may, in turn, 
prevent loss of energy and thereby benefit the 
ischemic myocardium. 2 Factors, other than electro- 
physiologic effects, such as reduction of calcium 
release from the sarcoplasmic reticulum or de- 
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Fig. 6. Recovery of LVDP and balloon volume (at an 
LVEDP of 4 mm Hg) after 100 minutes of low-flow per- 
fusion or continuous infusion of warm cardioplegic solu- 
tion with or without nicorandil (10/.~mol/L) (9hearts per 
group). Values are presented as means plus or minus 
standard error of mean. *p < 0.05. 
creased sensitivity of the contractile lements to 
calcium may also be involved. 13 
The protective actions of nicorandil during con- 
tinuous delivery of low-flow warm cardioplegic so- 
lution. The precise mechanism underlying the 
protective ffect of nicorandil during continuous 
cardioplegia is not clear. It has been shown that 
the myocardium of hearts receiving continuous 
cardioplegia conserves tissue high-energy phos- 
phates better than ischemic myocardium. 5' 14 As a 
consequence, it may well be that ATP-sensitive 
potassium channels are less likely to be activated 
during low-flow ischemia. Under these conditions, 
nicorandil may activate potassium channels and 
thereby accelerate cardiac arrest by increasing the 
1070 Qiu, Galit~anes, Hearse 
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Table IV. Tissue ATP and creatine phosphate content and CK leakage after cardioplegia nd low-flow 
perfusion (9 hearts per group) 
Study A TP CP CK leakage 
group Treatment (i.tmol/gm dry wt) (p.mol/gm dry wt) (IU/40 min/gm dry wt) 
1 Low-flow 14.6 + 2.6 26.6 _+ 6.8 104.0 _+ 15.0 
2 Low-flow + nicorandil 14.2 _+ 3.2 24.8 _+ 5.6 88.4 -+ 15.7 
3 Cardioplegia 15.5 _+ 2.8 25.6 -+ 4.2 85.5 -+ 22.8 
4 Cardioplegia + nicorandil 19.1 +__ 3.1 29.1 +_ 4.5 99.8 _+ 20.2 
Data expressed as means plus or minus standard error of mean. CP, Creatine phosphate. 
extracellular potassium concentration, thereby in- 
ducing hyperpolarization. A further consideration 
is that, in the present studies with continuous 
cardioplegia, the extracellular potassium concen- 
tration was only about 10 mmol/L. This concen- 
tration on its own may be inadequate to induce a 
degree of depolarization that would block myo- 
cardial contraction under conditions of normo- 
thermia nd continuous perfusion. In such a situ- 
ation, potassium-channel activation may increase 
potassium conductance and accelerate cardiac 
arrest. 15 
The protective actions of nicorandil during low- 
flow ischemia. In the present study, a protective 
effect of nicorandil was also demonstrated in hearts 
subjected to low-flow perfusion (without cardiople- 
gia). The infusion of nicorandil significantly de- 
pressed cardiac electrical activity during the first 10 
minutes of ischemia nd also improved the recovery 
of postischemic LVDP. 
Nicorandil and the diastolic state. Our studies 
demonstrated that left ventricular compliance was 
better preserved by nicorandil in low-flow isch- 
emia both with and without cardioplegia. This was 
evidenced by the fact that the balloon volume 
required to achieve an LVEDP of 4 mm Hg was 
significantly greater in the nicorandil-treated 
groups. However, when the same volume of water 
was introduced into the balloons of both groups, 
there was no significant difference in LVDP be- 
tween nicorandil-treated and nicorandil-free 
groups (Qiu, Galifianes, and Hearse, unpublished 
data). This observation may suggest that the pro- 
tective effect of nieorandil is exerted mainly on 
diastolic function. 
It is unclear why, after 15 minutes of low-flow 
ischemia, nicorandil did not continuously depress 
electrical activity. However, we could speculate that 
during the later period of ischemia, potassium- 
channel activation o longer plays an important role 
in maintaining cardiac arrest 16 and that stimulatory 
factors (such as the accumulation of intracellular 
calcium) may determine contractile status at this 
time. 
Studies with nicorandil pretreatment before zero- 
flow ischemia. Pretreatment with nicorandil alone 
had no significant protective ffect on postisch- 
emic LVDP or LVEDP, nor did it affect he time 
to onset of ischemic ontracture. However, there 
was a statistically significant effect on the time to 
cardiac arrest and an improvement in the recovery 
of coronary flow was also recorded. It is possible 
that the higher prevalence of reperfusion-induced 
arrhythmias in the nicorandil group may have 
impaired the recovery of contractile function, thus 
masking any inherent protective ffect of the drug 
on the recovery of LVDP. Another possible ex- 
planation for the failure of pretreatment to im- 
prove postischemic LVDP might relate to the 
dosage selected. In this connection, Grover, 
Sleph, and Parham, 17 using the isolated rat heart, 
reported that, although pretreatment with nic- 
orandil at doses of 10 and 100 ~Lmol/L did not 
improve the recovery of contractile function after 
25 minutes of normothermic global ischemia, in- 
creasing the dose to 300 /~mol/L resulted in a 
significant improvement. Another recently re- 
ported study with guinea pig papillary muscle 
preparations also indicated that pretreatment 
with nicorandil at a concentration f i mmol/L for 
15 minutes, although it induced a significant neg- 
ative inotropism, could enhance the recovery of 
contractile function after long-term hypoxia, a8 
However, in the present study, we did not use 
doses of nicorandil higher than 100 txmol/L owing 
to the significant negative inotropic effect that 
would result from the use of such a dosage. 
Drug dose and arrhythmogenesis. Several in 
vivo and in vitro studies have demonstrated that 
high doses of nicorandil can exert a negative 
inotropic effect and induce arrhythmias. .9'2o Thus 
Kojima and associates 19reported that the intra- 
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coronary administration of large doses (1 mg or 
more, as a bolus infusion) of nicorandil sup- 
pressed myocardial contractility in areas of re- 
gional ischemia and precipitated ventricular ar- 
rhythmias (including VF) in dog hearts. However, 
they also reported that they had found a "safe 
dose" that effectively produced coronary vasodi- 
lation without deleterious mechanical or electrical 
effects. In the present study, nicorandil at a dose 
of 100 ~mol/L given for 3 minutes before ischemia 
was shown to suppress LVDP significantly and 
when used at a dose of 10 /xmol/L to increase 
significantly the susceptibility of the heart to 
reperfusion-induced arrhythmias including VF. 
These doses were within the concentration range 
required to accelerate the appearance of cardiac 
arrest and to improve the recovery of coronary 
flow. It appears therefore that, at least in the 
present model, the optimal dose range for nic- 
orandil may be relatively narrow. Nevertheless, it 
should be noted that arrhythmogenic effects have 
been reported with other potassium-channel 
openers such as lemakalim. 21 Awareness of this 
proper-ty may be important when potassium-chan- 
nel openers are used experimentally or clinically 
as cardioprotective agents. Furthermore,  although 
the results of the present study revealed the 
beneficial effects of nicorandil as an additive to 
the solution used for continuous warm crystalloid 
cardioplegia, it is important hat these findings be 
evaluated in in vivo preparations, especially with 
sanguineous cardioplegia. 
We gratefully acknowledge the advice and discussion of 
Drs. M. J. Shattock and W. A. Coetzee. 
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Notice of correction 
In the August 1994 issue of the JOURNAL, in the article by Ballmer and associates titled 
"Depletion of Plasma Vitamin C but not of Vitamin E in Response to Cardiac Operations," an 
error was made. On page 312, column 2, the formula for the correction for hemodilution of 
plasma vitamin concentrations should read as follows: "Corrected values of the measured 
plasma concentrations of all three vitamins were calculated by multiplying the vitamin 
concentration by 100 - baseline hematocrit/100 - actual hematocrit." 
